chartexchange

Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology

GlobeNewswire Inc. | Nov 9, 2026 11:00 AM EST

Publication reinforces miv-cel's potential to deliver durable clinical benefit with a single dose, enabled by miv-cel's unique construct, and become the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease

Read original article